Clin2
NCT07610369Possibly a fitRecruiting

Psilocybin therapy for depression in Parkinson's disease

DepressionParkinson's Disease (PD)

Treatments studied

Part of Brain & nervous system clinical trials.

This study tests whether psilocybin (a psychedelic compound) combined with therapy can reduce depression in people with Parkinson's disease. If you have moderate-to-severe depression and Parkinson's, this trial may offer a new treatment option.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
40 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • You have neurologist-diagnosed Parkinson's disease (early-to-moderate stages) that is currently controlled with medication
  • You have moderate or severe depression (a specific screening test will confirm this)
  • You are willing to avoid many common medications, supplements, and substances for specific periods before and after treatment sessions
  • You have no serious psychiatric conditions like schizophrenia, bipolar disorder, or recent suicidal thoughts
  • You have a primary care doctor or neurologist actively involved in your care who can consult with the study team
  • You can understand English, provide informed consent, and commit to not changing your Parkinson's medications during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06455293Recruiting· Phase 2
Psilocybin therapy for depression in Parkinson's disease

This study tests whether psilocybin, a substance found in certain mushrooms, can help improve depression in people with Parkinson's disease. If you have Parkinson's and are feeling depressed, this treatment may offer a new option.

San Francisco, California
NCT07582120Not yet recruiting· Phase 2
Psilocybin-Assisted Therapy for Depression

This study tests whether psilocybin (a naturally occurring psychedelic compound) combined with therapy can help treat depression. Researchers will give you a single dose of psilocybin in a controlled medical setting while providing psychological support to see if it reduces your depression symptoms.

St Louis, Missouri
NCT05568498Recruiting· Phase 2
Probiotic trial for depression in Parkinson’s disease

This Phase 2 study tests whether taking probiotics can improve depression and mood symptoms in people with Parkinson’s disease. It’s meant for those with mild to moderate depression and stable Parkinson’s and mood treatments.

Vancouver, British Columbia
NCT06512194Recruiting· Phase 2
Psilocybin for depression study

This trial tests whether psilocybin can help people with major depression who are currently having a depressive episode. It aims to understand how the treatment works and if it is safe and effective.

Edwards, Colorado
NCT06247839Recruiting· Phase 3
Psilocybin for depression: changing self-focus

This trial tests whether a single dose of psilocybin can help people with treatment-resistant depression by changing how they focus on themselves. It aims to understand how psilocybin affects brain activity and self-related thinking.

Charlestown, Massachusetts
NCT06592833Recruiting· Phase 2
Psilocybin with or without pimavanserin for depression

This study tests whether combining psilocybin (a psychedelic substance) with pimavanserin (a medication that may help reduce side effects) works better than psilocybin alone for treating major depressive disorder. It may help people who have not responded well to other treatments.

New York, New York

Hear when a new Depression trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.